Search results for "surgical oncology"

showing 10 items of 84 documents

Detection of circulating miRNAs: comparative analysis of extracellular vesicle-incorporated miRNAs and cell-free miRNAs in whole plasma of prostate c…

2017

Abstract Background Circulating cell-free miRNAs have emerged as promising minimally-invasive biomarkers for early detection, prognosis and monitoring of cancer. They can exist in the bloodstream incorporated into extracellular vesicles (EVs) and ribonucleoprotein complexes. However, it is still debated if EVs contain biologically meaningful amounts of miRNAs and may provide a better source of miRNA biomarkers than whole plasma. The aim of this study was to systematically compare the diagnostic potential of prostate cancer-associated miRNAs in whole plasma and in plasma EVs. Methods RNA was isolated from whole plasma and plasma EV samples from a well characterised cohort of 50 patient with …

0301 basic medicineAdultMaleCancer ResearchPathologymedicine.medical_specialtyExosomeslcsh:RC254-282Cohort Studies03 medical and health sciencesProstate cancer0302 clinical medicineSurgical oncologyProstatemicroRNAGeneticsBiomarkers TumorMedicineHumansCell-free miRNAsCirculating MicroRNALiquid biopsyAgedAged 80 and overProstate cancerLiquid biopsybusiness.industryCancerProstatic NeoplasmsExtracellular vesicleMiddle AgedExtracellular vesicleslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseMicrovesiclesMicroRNAs030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer researchbusinessMicrovesiclesBiomarkersResearch ArticleBMC cancer
researchProduct

NOTCH3 expression is linked to breast cancer seeding and distant metastasis

2018

Background Development of distant metastases involves a complex multistep biological process termed the invasion-metastasis cascade, which includes dissemination of cancer cells from the primary tumor to secondary organs. NOTCH developmental signaling plays a critical role in promoting epithelial-to-mesenchymal transition, tumor stemness, and metastasis. Although all four NOTCH receptors show oncogenic properties, the unique role of each of these receptors in the sequential stepwise events that typify the invasion-metastasis cascade remains elusive. Methods We have established metastatic xenografts expressing high endogenous levels of NOTCH3 using estrogen receptor alpha-positive (ERα+) MCF…

0301 basic medicineCancer ResearchTransplantation HeterologousNotch signaling pathwayEstrogen receptorMice NudeBreast NeoplasmsTriple Negative Breast NeoplasmsTumor stemneCentrosome amplificationTumor stemnessMetastasilcsh:RC254-282MetastasisMetastasis03 medical and health sciences0302 clinical medicineBreast cancerNeoplasm SeedingBreast cancerSurgical oncologyCell Line TumormedicineAnimalsHumansCell Self RenewalReceptor Notch3business.industryGene Expression ProfilingMiddle Agedmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrimary tumorSurvival Analysis3. Good healthChromosomal instabilityGene Expression Regulation NeoplasticSettore BIO/18 - Genetica030104 developmental biologyOncology030220 oncology & carcinogenesisCancer cellCancer researchMCF-7 CellsFemaleRNA InterferencebusinessBrain metastasisResearch ArticleBreast Cancer Research
researchProduct

ASO Author Reflections: How Long will We Perform Lymphadenectomy in Endometrial Cancer Patients?

2022

Abstract Objectives To compare survival and progression outcomes between 2 nodal assessment approaches in patients with nonbulky stage IIIC endometrial cancer (EC). Methods Patients with stage IIIC EC treated at 2 institutions were retrospectively identified. At 1 institution, a historical series (2004–2008) was treated with systematic pelvic and para-aortic lymphadenectomy (LND cohort). At the other institution, more contemporary patients (2006–2013) were treated using a sentinel lymph node algorithm (SLN cohort). Outcomes (hazard ratios [HRs]) within the first 5 years after surgery were compared between cohorts using Cox models adjusted for type of adjuvant therapy. Results The study incl…

0301 basic medicineN.A.medicine.medical_specialtymedicine.medical_treatmentSentinel lymph nodeMEDLINEArticleEndometrial CancerDisease-Free Survival03 medical and health sciences0302 clinical medicineLymphadenectomy Endometrial CancerSurgical oncologyAdjuvant therapymedicineHumansStage IIICNeoplasm InvasivenessProgression-free survivalLymph nodeAgedNeoplasm StagingRetrospective Studiesbusiness.industryEndometrial cancerGeneral surgeryObstetrics and GynecologyLymphadenectomymedicine.diseaseEndometrial Neoplasms030104 developmental biologymedicine.anatomical_structureTreatment OutcomeSettore MED/40 - GINECOLOGIA E OSTETRICIASentinel nodeOncology030220 oncology & carcinogenesisLymphatic MetastasisDisease ProgressionLymph Node ExcisionFemaleSurgeryLymphadenectomySentinel Lymph NodebusinessAlgorithmChemoradiotherapyAlgorithmsAnnals of Surgical Oncology
researchProduct

Hepatoceliac Lymph Node Involvement in Advanced Ovarian Cancer Patients: Prognostic Role and Clinical Considerations.

2017

Background: The study aimed too investigate the rate of hepatoceliac lymph node (HCLN) involvement, as well as its association with clinicopathologic features, together with morbidity of HCLN resection and the prognostic impact of metastatic HCLN status on patients with advanced ovarian cancer (OC) undergoing cytoreductive surgery. Methods: All consecutive patients with stages 3c to 4 epithelial OC who underwent HCLN surgery from January 2010 to September 2016 were analyzed for surgical procedures, pathology, and oncologic outcomes. Results: During the study period, 85 patients underwent HCLN resection. Absence of visible tumor at the end of surgery was documented for 73 of the patients (85…

0301 basic medicineOncologyAdultmedicine.medical_specialtyMetastasis03 medical and health sciencesYoung Adult0302 clinical medicineSurgical oncologyCeliac ArteryInternal medicinemedicineHumansYoung adultCystadenocarcinomaSurvival rateLymph nodeAgedRetrospective StudiesOvarian Neoplasmsbusiness.industryLiver NeoplasmsRetrospective cohort studyCytoreduction Surgical ProceduresMiddle Agedmedicine.diseaseovarian cancer hepatoceliac lymph nodes metastasesPrognosisCystadenocarcinoma SerousEndometrial NeoplasmsSurvival Rate030104 developmental biologymedicine.anatomical_structureSettore MED/40 - GINECOLOGIA E OSTETRICIAOncology030220 oncology & carcinogenesisLymphatic MetastasisSurgery; OncologyAdenocarcinomaLymph Node ExcisionSurgeryFemaleLymph NodesbusinessAdenocarcinoma Clear CellFollow-Up StudiesAnnals of surgical oncology
researchProduct

PTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival.

2017

Background: PTTG1-interacting protein (PTTG1IP) is an oncogenic protein, which participates in metaphase-anaphase transition of the cell cycle through activation of securin (PTTG1). PTTG1IP promotes the shift of securin from the cell cytoplasm to the nucleus, allowing the interaction between separase and securin. PTTG1IP overexpression has been previously observed in malignant disease, e.g. in breast carcinoma. However, the prognostic value of PTTG1IP in breast carcinoma patients has not previously been revealed. Methods: A total of 497 breast carcinoma patients with up to 22-year follow-up were analysed for PTTG1IP and securin immunoexpression. The results were evaluated for correlations w…

0301 basic medicineOncologyCancer ResearchTriple Negative Breast NeoplasmsKaplan-Meier EstimatePBF0302 clinical medicineBreast cancerSurgical oncologyRisk FactorsAged 80 and overrintasyöpäPTTG1 interacting proteinIntracellular Signaling Peptides and ProteinsCell cycleMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisImmunohistochemistrySecurinsyöpägeenitOncologySecurin030220 oncology & carcinogenesisImmunohistochemistryFemaleSeparaseBreast carcinomaResearch ArticleAdultmedicine.medical_specialtyPTTG1IPBreast Neoplasmslcsh:RC254-282immunohistokemia03 medical and health sciencesBreast cancerInternal medicineGeneticsmedicineBiomarkers TumorHumansAgedbusiness.industryMembrane Proteinsmedicine.disease030104 developmental biologyMultivariate AnalysisCancer researchprognosisproteiinitbusinessBMC cancer
researchProduct

Alternative lengthening of telomeres (ALT) influences survival in soft tissue sarcomas: a systematic review with meta-analysis

2019

Background Alternative lengthening of telomeres (ALT) is a telomerase-independent mechanism used by a broad range of neoplasms to maintain telomere length, permitting uncontrolled replication during their progression. ALT has been described in different types of sarcoma, but a comprehensive analysis of its clinical significance is still lacking. Therefore, we provide here the first meta-analysis on this topic. Methods We searched SCOPUS and PubMed through July 2018 to identify all studies that investigated the prognostic role of ALT in sarcomas. We considered the risk of death (risk ratio, RR) calculated as the number of death vs. total participants during follow-up in ALT+ versus ALT- pati…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyMultivariate analysisMesenchymalSurvivalALTlcsh:RC254-282digestive systemRisk Assessmentnot known03 medical and health sciences0302 clinical medicineSurgical oncologyInternal medicineGeneticsmedicineHumansClinical significanceALT; ATR; ATRX; Mesenchymal; Prognosis; Sarcoma; SurvivalProportional Hazards Modelsbusiness.industryHazard ratioSoft tissueTelomere HomeostasisSarcomaMiddle AgedTelomeremedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisSurvival Analysisdigestive system diseases3. Good health030104 developmental biologyATRATRXOncology030220 oncology & carcinogenesisRelative riskMeta-analysisSarcomabusinessResearch ArticleBMC Cancer
researchProduct

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study

2019

BackgroundEribulin mesylate (E) is indicated for metastatic breast cancer patients previously treated with anthracycline and taxane. We argued that E could also benefit patients eligible for neoadjuvant chemotherapy.MethodsPatients with primary triple negative breast cancer ≥2 cm received doxorubicin 60 mg/m2 and paclitaxel 200 mg/m2 x 4 cycles (AT) followed by E 1.4 mg/m2 x 4 cycles. Primary endpoint was pathological complete response (pCR) rate; secondary and explorative endpoints included clinical/metabolic response rates and safety, and biomarker analysis, respectively. Using a two-stage Simon design, 43 patients were to be included provided that 4 of 13 patients had achieved pCR in the…

0301 basic medicineOncologyCancer TreatmentTriple Negative Breast NeoplasmsImmunostainingToxicologyPathology and Laboratory MedicineBiochemistryMetastasis0302 clinical medicineBreast TumorsClinical endpointMedicine and Health Sciencesmetastatic breast cancer Eribulin mesylate epithelial–mesenchymal transition.AnthracyclinesTriple-negative breast cancerStainingMultidisciplinaryPharmaceuticsQRKetonesMetastatic breast cancerNeoadjuvant TherapyTreatment OutcomeSurgical OncologyOncology030220 oncology & carcinogenesisMedicineFemaleTaxoidsResearch ArticleAdultBridged-Ring CompoundsClinical Oncologymedicine.medical_specialtyAnthracyclineScienceSurgical and Invasive Medical ProceduresNeutropeniaResearch and Analysis Methods03 medical and health sciencesCancer ChemotherapyBreast cancerbreast cancerDrug TherapyInternal medicinemedicineHumansChemotherapyFuransTaxaneToxicitybusiness.industryCancers and NeoplasmsBiology and Life Sciencesmedicine.disease030104 developmental biologySpecimen Preparation and TreatmentMED/06 - ONCOLOGIA MEDICAClinical MedicinebusinessBiomarkers
researchProduct

Giant hepatocellular adenoma as cause of severe abdominal pain: a case report

2007

Abstract The authors describe the case of a large hepatocellular adenoma diagnosed in a 30-year old woman who came to us complaining of acute pain in the upper abdominal quadrants. The patient had been taking an oral contraceptive pill for the last ten years. We present the clinical features, the diagnostic work-up and the treatment prescribed.

Abdominal painPathologyoral contraceptive agent EMTREE medical terms: abdominal painanamnesilcsh:Medicinecomputer assisted tomographyaspartate aminotransferaseSurgical oncologynuclear magnetic resonance imagingMedicine(all)oral contraceptionadultarticleGeneral MedicineAbdominal quadrantsfemalepriority journalhistopathologycontrast enhancementdisease severitymedicine.symptomEMTREE drug terms: alanine aminotransferasemedicine.medical_specialtyOral contraceptive pillcontrast mediummedicinediffusion weighted imagingcase reportfollow uphumanAcute painliver biopsydrug useliver lobectomybusiness.industryGeneral surgeryPublic healthlcsh:RechographyHepatocellular adenomaliver angiographymedicine.diseasetumor bleedinghuman tissueclinical featurenausea and vomitingbusinessaspartate aminotransferase blood levelliver adenomaalanine aminotransferase blood level
researchProduct

Primitive Neuroectodermal Tumor (PNET) of the kidney: a case report.

2004

Abstract Background A case of Primitive Neuroectodermal Tumor (PNET) of the kidney in a 27-year-old woman is presented. Few cases are reported in the literature with a variable, nonspecific presentation and an aggressive behaviour. In our case, a radical nephrectomy with lymphadenectomy was performed and there was no residual or recurrent tumour at 24-month follow-up. Methods The surgical specimens were formalin-fixed and paraffin embedded. The sections were stained with routinary H&E. Immunohistochemistry was performed. Results The immunohistochemical evaluation revealed a diffuse CD99 positivity in the cytoplasm of the neoplastic cells. Pankeratin, cytokeratin AE1/AE3, vimentin, desmin, S…

AdultEwing's SarcomaPNETCancer ResearchPathologymedicine.medical_specialtyRenal PNETmedicine.medical_treatmentCD99Case Reportlcsh:RC254-282Diagnosis DifferentialCytokeratinImmunophenotypingSurgical oncologystem cellsGeneticsmedicineHumansNeuroectodermal Tumors Primitive Peripheralrhabdomyosarcoma tumorbusiness.industryEwing's sarcomalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseNephrectomyKidney NeoplasmsOncologyPrimitive neuroectodermal tumorFemaleDifferential diagnosisbusinesscarcinogenesis
researchProduct

How to select early-stage cervical cancer patients still suitable for laparoscopic radical hysterectomy: a propensity-matched study

2020

Background: Recently, it was reported that minimally invasive surgery (MIS) has a negative impact on early-stage cervical cancer (ECC) patient survival. At the same time, advantages of MIS regarding quality of life and low rate of intra- and postoperative complications are well known. Therefore, it is essential to select patients who may benefit from MIS without worsening their oncologic outcomes. The aim of this study is to investigate which pathological factors could guide surgeons’ choice about the best approach in ECC. Patients and Methods: Patients with 2009 FIGO stage from IA1 with lymphovascular space invasion (LVSI) to IB1/IIA1 treated by open or laparoscopic surgery were judged eli…

AdultLaparoscopic surgerymedicine.medical_specialtymedicine.medical_treatmentlaparoscopyUterine Cervical NeoplasmsHysterectomyDisease-Free Survivalopen surgeryYoung Adult03 medical and health sciences0302 clinical medicineSurgical oncologymedicineHumansMinimally Invasive Surgical ProceduresRadical HysterectomyPropensity ScoreLaparoscopyGrading (tumors)minimally invasive surgeryAgedNeoplasm StagingRetrospective StudiesAged 80 and overCervical cancermedicine.diagnostic_testbusiness.industryParametrialCervical cancer; laparoscopy; minimally invasive surgery; open surgery; radical hysterectomy; tumor diameterHazard ratioMiddle Agedmedicine.diseaseSurgerySurvival RateTreatment OutcomeSettore MED/40 - GINECOLOGIA E OSTETRICIAItalyOncology030220 oncology & carcinogenesisradical hysterectomyCervical cancerFemale030211 gastroenterology & hepatologySurgerytumor diameterbusiness
researchProduct